 Neoplasm Grading
"Neoplasm Grading" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
| Descriptor ID |
D060787
|
| MeSH Number(s) |
E01.789.612
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Grading".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Grading".
This graph shows the total number of publications written about "Neoplasm Grading" by people in this website by year, and whether "Neoplasm Grading" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 | | 2011 | 0 | 4 | 4 | | 2012 | 0 | 7 | 7 | | 2013 | 1 | 15 | 16 | | 2014 | 2 | 18 | 20 | | 2015 | 0 | 19 | 19 | | 2016 | 0 | 12 | 12 | | 2017 | 0 | 20 | 20 | | 2018 | 1 | 16 | 17 | | 2019 | 0 | 20 | 20 | | 2020 | 0 | 14 | 14 | | 2021 | 0 | 7 | 7 | | 2022 | 0 | 3 | 3 | | 2023 | 0 | 1 | 1 | | 2024 | 0 | 8 | 8 | | 2025 | 0 | 4 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm Grading" by people in Profiles.
-
Mehari M, Warrier G, Dada A, Kabir A, Haskell-Mendoza AP, Tripathy A, Jha R, Nieblas-Bedolla E, Jackson JD, Gonzalez AT, Reason EH, Flusche AM, Reihl S, Dalton T, Negussie M, Gonzales CN, Ambati VS, Desjardins A, Daniel AGS, Krishna S, Chang S, Porter A, Fecci PE, Hollon T, Chukwueke UN, Badal K, Molinaro AM, Hervey-Jumper SL. Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning. Sci Adv. 2025 Jun 06; 11(23):eadt5708.
-
Lawson-Michod KA, Marks JR, Collin LJ, Nix DA, Davidson NR, Huff CD, Yu Y, Atkinson A, Johnson CE, Salas LA, Peres LC, Greene CS, Schildkraut JM, Doherty JA. Genomic Characterization of High-Grade Serous Ovarian Carcinoma Reveals Distinct Somatic Features in Black Individuals. Cancer Res. 2025 May 02; 85(9):1725-1737.
-
Alqaisi HA, Cohn DE, Chern JY, Duska LR, Jewell A, Corr BR, Winer IS, Girda E, Crispens MA, Dhani NC, Madariaga A, Grant RC, Malaguti M, Lee C, Bowering V, Wong H, Poothullil A, Speers V, Wang L, Bedard PL, Brady JC, Nixon AB, Chen L, O'Connor C, Zamboni W, McKee T, Moscow JA, Oza AM, Lheureux S. Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial). Clin Cancer Res. 2025 Mar 17; 31(6):993-1001.
-
Fathi Kazerooni A, Kraya A, Rathi KS, Kim MC, Vossough A, Khalili N, Familiar AM, Gandhi D, Khalili N, Kesherwani V, Haldar D, Anderson H, Jin R, Mahtabfar A, Bagheri S, Guo Y, Li Q, Huang X, Zhu Y, Sickler A, Lueder MR, Phul S, Koptyra M, Storm PB, Ware JB, Song Y, Davatzikos C, Foster JB, Mueller S, Fisher MJ, Resnick AC, Nabavizadeh A. Multiparametric MRI along with machine learning predicts prognosis and treatment response in pediatric low-grade glioma. Nat Commun. 2025 Jan 02; 16(1):340.
-
Van Kleunen LB, Ahmadian M, Post MD, Wolsky RJ, Rickert C, Jordan KR, Hu J, Richer JK, Brubaker LW, Marjon N, Behbakht K, Sikora MJ, Bitler BG, Clauset A. The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma. Cancer Immunol Res. 2024 Nov 04; 12(11):1492-1507.
-
Epperla N, Zayac AS, Landsburg DJ, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman A, Li S, Medeiros LJ, Chang JE, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi Y, Bond DA, Evens AM, Naik SG, Kamdar M, Haverkos BM, Karmali R, Farooq U, Vose JM, Rubinstein P, Chaudhry A, Olszewski AJ. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood Adv. 2024 10 22; 8(20):5355-5364.
-
Morrow K, Sloan A, Olson JJ, Ormond DR. Congress of Neurological Surgeons systematic review and evidence-based guidelines on the management of recurrent diffuse low-grade glioma: update. J Neurooncol. 2025 Jan; 171(1):105-130.
-
Davidson NR, Barnard ME, Hippen AA, Campbell A, Johnson CE, Way GP, Dalley BK, Berchuck A, Salas LA, Peres LC, Marks JR, Schildkraut JM, Greene CS, Doherty JA. Molecular Subtypes of High-Grade Serous Ovarian Cancer across Racial Groups and Gene Expression Platforms. Cancer Epidemiol Biomarkers Prev. 2024 Aug 01; 33(8):1114-1125.
-
Saha A, Bosma JS, Twilt JJ, van Ginneken B, Bjartell A, Padhani AR, Bonekamp D, Villeirs G, Salomon G, Giannarini G, Kalpathy-Cramer J, Barentsz J, Maier-Hein KH, Rusu M, Rouvi?re O, van den Bergh R, Panebianco V, Kasivisvanathan V, Obuchowski NA, Yakar D, Elschot M, Veltman J, F?tterer JJ, de Rooij M, Huisman H. Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study. Lancet Oncol. 2024 Jul; 25(7):879-887.
-
Ueberroth BE, Lieu CH, Lentz RW. Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation. J Gastrointest Cancer. 2024 Sep; 55(3):1448-1452.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|